Medicare is expanding its drug price negotiation program to include 15 more medications, including popular drugs like Ozempic.

The Inflation Reduction Act of 2022 marked a significant shift in US health care policy, granting the Centers for Medicare and Medicaid Services (CMS) the authority to establish a program to negotiate ...

The Trump administration, perhaps surprisingly, chose to defend the legality of the Inflation Reduction Act’s (IRA’s) drug ...

The U.S. Department of Justice has filed an appeals court brief supporting the right of Medicare officials to negotiate ...

Records show that drug companies gave nearly $75,000 to the top Republican and Democrat on a committee investigating them.

Novo Nordisk's NovoCare will now provide uninsured or underinsured patients access to Wegovy for just $499 per month—less ...

At least three government lawyers working on defending a major Biden-era drug pricing law were laid off in mass cuts across ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

Pharmacy benefit managers take considerably different approaches to managing patient access to biosimilars, or cheaper ...

A federal court rejected Novartis' legal challenge to the Medicare Drug Price Negotiation Program, ruling that it does not ...

Cost Plus Drugs inked deals with MultiCare Health System, Network Health, Blue Cross and Blue Shield insurers and others ...

NovoCare Pharmacy will provide all dose strengths of Wegovy at a reduced cost of $499 per month for cash-paying patients without insurance.